Despite posting record Q2 growth for its blockbuster weight loss and diabetes drug tirzepatide, Eli Lilly is facing legal ...

Amphastar has signed an exclusive license agreement with Anji for the development, production, use and commercialisation of 3 ...

PureTech's latest spinoff Celea Therapeutics was created to progress the former's lead respiratory IPF programme, ...

Insmed’s drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...

Ovarian cancer is one of the most challenging malignancies in oncology. Despite advances in diagnosis and treatment, it is ...

Our editorial team dives into the pharma industry's reaction to US tariffs on imports from the European Union and major trends from Q2 earnings calls.

Fosun Pharma Industrial has entered a licence agreement to grant ex-China rights for its respiratory drug, XH-S004, to Expedition.

Vinay Prasad resumes leadership at the FDA’s CBER two weeks after he resigned amid cell and gene therapy controversy.

Sartorius has agreed to invest $3m in Nanotein Technologies, engaged in the development of advanced immune cell activation reagents.

As tariffs on drug imports from the EU look set to alter pricing and manufacturing strategies, each entity needs to study its full impact.

South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

Genmab and AbbVie’s Epkinly has met its dual primary endpoints as a second-line combination therapy in relapsed/refractory ...